anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cyclosporine Capsules, USP (NON-MODIFIED) have decreased bioavailability in comparison to Neoral®* (cyclosporine capsules, USP) MODIFIED. Cyclosporine Capsules, USP (NON-MODIFIED) and Neoral®* (cyclosporine capsules, USP) MODIFIED are not bioequivalent and cannot be used interchangeably without physician supervision.

The initial oral dose of Cyclosporine Capsules, USP NON-MODIFIED should be given 4 to 12 hours prior to transplantation as a single dose of 15 mg/kg. Although a daily single dose of 14 to 18 mg/kg was used in most clinical trials, few centers continue to use the highest dose, most favoring the lower end of the scale. There is a trend towards use of even lower initial doses for renal transplantation in the ranges of 10 to 14 mg/kg/day. The initial single daily dose is continued postoperatively for 1 to 2 weeks and then tapered by 5% per week to a maintenance dose of 5 to 10 mg/kg/day. Some centers have successfully tapered the maintenance dose to as low as 3 mg/kg/day in selected renal transplant patients without an apparent rise in rejection rate.

(See Blood Level Monitoring below.)

In pediatric usage, the same dose and dosing regimen may be used as in adults although in several studies, children have required and tolerated higher doses than those used in adults.

Adjunct therapy with adrenal corticosteroids is recommended. Different tapering dosage schedules of prednisone appear to achieve similar results. A dosage schedule based on the patient’s weight started with 2.0 mg/kg/day for the first 4 days tapered to 1.0 mg/kg/day by 1 week, 0.6 mg/kg/day by 2 weeks, 0.3 mg/kg/day by 1 month, and 0.15 mg/kg/day by 2 months and thereafter as a maintenance dose. Another center started with an initial dose of 200 mg tapered by 40 mg/day until reaching 20 mg/day. After 2 months at this dose, a further reduction to 10 mg/day was made. Adjustments in dosage of prednisone must be made according to the clinical situation.

Cyclosporine Capsules, USP NON-MODIFIED should be administered on a consistent schedule with regard to time of day and relation to meals.
Digital health approaches are promising intervention channels for improving DASH diet adherence. Almost all Americans own a mobile phone and 97% of mobile phone owners use text messaging. Digital health approaches can capitalize on the ubiquity of mobile technologies and allow investigators to reach affected populations with highly personalized content at low cost. Despite this ubiquity, interventions using text messaging for hypertension self-management primarily rely on reminders for tracking and medication adherence without diet and physical activity behaviors or feedback. As such, they are less effective. Investigators will establish the feasibility of a novel digital health-based approach for disseminating the DASH diet using the Amazon Alexa personal assistant. The data from this pilot feasibility trial will set the foundation for a larger, fully-powered R01 grant to examine whether DASH Cloud using Alexa can improve health outcomes. The primary aim of this proposal is to test the feasibility of the DASH Cloud intervention using Amazon Alexa.
FIELD: medicine. SUBSTANCE: wound- healing product is based upon well-available plant raw material and bee keeping products. The present ointment contains bee wax, honey, powder of plantain leaves, castor oil and butter taken at certain quantitative ratio. The ointment in question is of anesthetic, antiphlogistic, bactericidal and resolving actions. It affects wound surface, favors quicker restoration of affected tissue, considerably improves patient's state in more shortened terms and reveals high tolerance and no side effects. EFFECT: higher efficiency.
PURPOSE:To simply and surely diagnose liver cancer or cirrhosis by a method wherein an extracorporal diagnostic chemical which is composed mainly of an antianexin antibody is used and anexin is detected from body fluids or an extracted tissue. CONSTITUTION:An antianexin I monoclonal antibody 8, 1-3 or an antianexin II monoclonal antibody 1.6 is preferable as an antianexin antibody. Regarding the antianexin antibody, anexin is quantitatively determined from human fluids such as blood serum, urine or the like or an extracted tissue by using an ELISA method, an RIA method, a tissue staining method or the like. For example, in the case of the ELISA method which uses a peroxidase as a labeling agent, a sample to be inspected is fixed to a solid-phase material, an antibody solution is added, the sample is reacted, and after a cleaning operation is performed, a biotin-labeled secondary antibody is added, an enzyme labeling liquid is then added, and the sample is reacted. In addition, a peroxidase-coloring liquid is added, a coloring operation is stopped for a definite time, and the absorbance or the fluorescent intensity of the sample is measured. Then, a measured value is applied to a standard curve, the anexin in the specimen is quantitatively determined, it is compared with the amount of the anexin in a healthy person, and it is judged whether the specimen is positive or not.
PURPOSE:To obtain composite resin powder having good feeling of use and excellent ultraviolet preventing effect by firmly bonding inorganic powder to the surface of resin powder. CONSTITUTION:The composite resin powder is obtained by coating the surface of resin powder surface-treated by silicone treatment, amino acid treatment, metal soap treatment, lecithin treatment, dialkylphosphoric acid treatment, silica alumina treatment, wax treatment, fluorine treatment, etc., especially, treatment with a surfactant having a perfluoroalkyl group with zinc oxide, titanium oxide or iron oxide. The surface treating agent and the zinc oxide, etc., are used in amounts of 0.01-30wt.%, preferably 0.5-15wt.% and 2-500wt.%, preferably 10-100wt.%, respectively. Preferable average particle diameter of the resultant composite resin powder is in the range of 0.1-50mum, especially 0.2-20mum. It is preferable from the view point of effect for preventing ultraviolet rays to include 1-25wt.% of the composite resin powder in a cosmetic. Since the coating is carried out through surface treatment, coating with the inorganic powder is readily carried out and adhesion between the resin powder and the inorganic material is also extremely large.
Many patients with heart failure benefit from cardiac resynchronization therapy (CRT) which involves implantation of a pacemaker to improve the coordination of heart function. However, approximately 30-40% of patients fail to respond to this therapy with current selection criteria. We hypothesize that patients with echocardiographic and MRI measures of a high degree of LV mechanical dyssynchrony are more likely to benefit from CRT than patients with less baseline dyssynchrony. Severe LV remodeling as measured by MRI may also predict patients less likely to benefit from therapy. In addition, myocardial fibrosis/scarring as measured by MRI delayed enhancement imaging may predict segments or subjects less likely to respond to CRT even in patients without ischemic heart disease. In this study, patients with New York Heart Association class III - IV heart failure will undergo imaging and stress testing prior to CRT pacemaker implantation and 6 months later to determine predictors of response. Considering the complexity of the protocol and novelty of some aspects of the MRI examination, we consider this an exploratory observational protocol.
Polygenic risk scores (PRSs) enable early prediction of disease risk. Evaluating PRS performance for binary traits commonly relies on the area under the receiver operating characteristic curve (AUC). However, the widely used DeLong's method for comparative significance tests suffer from limitations, including computational time and the lack of a one-to-one mapping between test statistics based on AUC and R 2  . To overcome these limitations, we propose a novel approach that leverages the Delta method to derive the variance and covariance of AUC values, enabling a comprehensive and efficient comparative significance test. Our approach offers notable advantages over DeLong's method, including reduced computation time (up to 150-fold), making it suitable for large-scale analyses and ideal for integration into machine learning frameworks. Furthermore, our method allows for a direct one-to-one mapping between AUC and R 2  values for comparative significance tests, providing enhanced insights into the relationship between these measures and facilitating their interpretation. We validated our proposed approach through simulations and applied it to real data comparing PRSs for diabetes and coronary artery disease (CAD) prediction in a cohort of 28,880 European individuals. The PRSs were derived using genome-wide association study summary statistics from two distinct sources. Our approach enabled a comprehensive and informative comparison of the PRSs, shedding light on their respective predictive abilities for diabetes and CAD. This advancement contributes to the assessment of genetic risk factors and personalized disease prediction, supporting better healthcare decision-making.
BACKGROUND: Veterans transitioning to civilian life often have chronic pain from service-related musculoskeletal disorders (MSD) with higher risk for substance misuse. Many seek VA (Department of Veterans Affairs) compensation for MSD. Use of Screening, Brief Intervention, and Referral to Treatment for Pain Management (SBIRT-PM) by VA Post-9/11 Military2VA (M2VA) case managers presents an opportunity to engage these veterans in VA pain care and address substance misuse. Implementation facilitation might help case managers use SBIRT-PM and engage veterans in services to improve outcomes.
DESIGN: This study is a 2-cohort multisite cluster-randomized hybrid type 2 effectiveness-implementation trial. Within 2 separate cohorts of 14 VA sites each, sites will be allocated to receive an implementation strategy through the use of a constrained randomization procedure: virtual implementation facilitation or training-as-usual. Sites and M2VA case managers will receive the assigned implementation strategy to support use of SBIRT-PM. Recently discharged veterans (n = 1848) claiming service-connected MSD will be recruited, with case managers blind to veterans' study enrollment. The proportion of participants who receive any SBIRT-PM will be the primary implementation outcome. Veteran participants will complete baseline, 12-week, and 36-week assessments, irrespective of whether case managers conduct SBIRT-PM with them (intent-to-treat). Pain intensity and interference will be the primary clinical outcomes. The study emphasizes pragmatic over explanatory methodological features.
SUMMARY: This pragmatic trial will examine implementation facilitation versus training-as-usual in implementing SBIRT-PM to promote veteran engagement in nonpharmacological pain services. Using innovative methods to train and support VA case managers in SBIRT-PM, study outcomes could have broad implications for case management systems of care across the VA.
SBRT of 15 Gy will be given on day 1 of the first cycle. Nivolumab 6 mg/kg (up to 480 mg maximum) will be given on day 1 (± 3 days) of each 14-day treatment cycle until the progression of disease or maximum of 48 weeks, discontinuation due to toxicity, withdrawal of consent. Ipilimumab 1 mg/kg will be given on day 1 (± 3 days) twice in total every 6 weeks. Nivolumab will be administered as an IV infusion over 60 (± 5) minutes and then, after a 30 minutes rest period, ipilimumab will be administered as an IV infusion over 30 (± 5) minutes. Tocilizumab 8 mg/kg is given IV on day 1 (± 3 days) over 1-hour, repeated every 4 weeks. Tocilizumab infusion over 30 minutes is allowed after 5. infusion in the absence of infusion related events.
A polyergic medicament combination is used for treatment of toxic insufficiencies of coumarin derivs. as rodenticides in activating (by interaction of the therapeutic agents) the haemorrhagic and anti-haemostatic toxic effects so as to neutralise the effects favouring generation and development and also secondary physiological resistance, of harmful rodents to anticoagulants. Potentiation of the coumarin derivs. is improved by increasing the absorption, transport and concn. of anti-vitamin K. Protection of the anti-coagulant is achieved by coating by saturation with a paraffinic mineral oil. In the plasma the coumarin derivs. show a high affinity for proteins: 20% for beta and gamma-globulins, 50% for alpha-globulins and 90% for albumen.
The present disclosure relates to the field of biotechnology, and in particular. to a fusion protein for the treatment of metabolic diseases, a preparation method therefor and use thereof. The present disclosure provides a fusion protein, including a Glucagon analogue fragment and a long-acting protein unit fragment, the Glucagon analogue fragment including: a) a polypeptide fragment having an amino acid sequence shown in SEQ ID No. 81; or b) a polypeptide fragment that has an amino acid sequence having at least 90% sequence identity with SEQ ID NO. 81 and has a function of the polypeptide fragment defined in a). The fusion protein of the present disclosure has good stability and good hypoglycemic and weight loss effects for mice.
The present invention is concerned with novel monoclonal antibody L53 which binds strongly to a glycoprotein antigen associated with human tumors, including carcinomas of the colon, breast, and lung, as well as melanomas. The antibody binds to normal human cells to a much lesser degree than to tumor cells. The antibody finds use in diagnostic methods for as the detection of malignant cells associated with tumors. Also disclosed is a novel 70,000-75,000 dalton glycoprotein antigen recognized by MAb L53. The L53 antigen is found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is:   <IMAGE>  +TR  mino acid.
The invention belongs to the technical field of biomedical materials, and discloses a UCST type polymer with a bacterial targeting function, a preparation method and application thereof. The method comprises the following steps: taking an organic solvent as a reaction medium, carrying out polymerization reaction on acrylamide, acrylonitrile and modified glucose monomers under the action of a chain transfer agent and an initiator, and removing acetyl to obtain the UCST polymer with the bacteria targeting function. The structure of the polymer is shown in formula I. The polymer has the highest critical solution temperature and good biocompatibility. The polymer promotes the formation of bacterial aggregates and realizes the function of bacterial targeting. The polymers of the present invention are useful as antimicrobial carriers. The polymer has good coating capacity of antibacterial drugs (photo-thermal reagents), and after the photo-thermal reagents are loaded on the polymer, the in-situ sterilization effect of the photo-thermal reagents is greatly enhanced by the targeting function of the polymer on bacteria under the irradiation of infrared light.
The present invention discloses a Chinese medicine composition for treating aypnia. The Chinese medicine composition is obtained mainly by extracting and condensing the raw materials of 27.3%-72.7% of ginger-prepared pinellia tuber, 9.1%-45.5% of rhizome arisaematis (prepared), 4.5%-27.3% of poria cocos wolf, 2.7%-9.1% of Indian corn and 4.5%-18.2% of ophiopogon root. The Chinese medicine composition can be prepared to any common orally taken dosage form. According to the prescription of the invention, the effects of harmonizing stomach, lowering adverse Qi and eliminating phlegm are mainly achieved by ginger-prepared pinellia tuber. The effect of harmonizing stomach is additionally achieved by Indian corn. Additionally the rhizome arisaematis (prepared), poria cocos wolf are added for harmonizing stomach and eliminating phlegm along with the pinellia tuber. As the ginger-prepared pinellia tuber and rhizome arisaematis (prepared) are dry in property, the ophiopogon root is added for eliminating dryness and nourishing heart. Through the observation to the curative effect of clinical 299 patients, the stomach harmonizing sleep promoting pellet of the invention can treat insomnia andcan remarkably improve symptom and sign. The total effectiveness rate is 78%. Furthermore the Chinese medicine composition of the invention has the advantages of safety, effectiveness, controllable quality, no toxic and side effect, and suitability for large-scale industrial production.
Esophageal cancer ranks the eighth most common cancer (the fifth most common cancer in China), while ESCC is the most common subtype in Asia (more than 90 % in china). Radical resection is thought to be the mainstay of esophageal cancer treatment and preoperative CRT is well applied in treating locally advanced esophageal cancer. In a multicohort, phase IB study, pembrolizumab was used in 23 unresectable esophageal cancer patients. In this clinical trial, the incidence of grade 3 treatment-related adverse events was 39 % without the appearance of grade 4 and higher-grade adverse event, while the overall response rate reached 30 %. The safety of immune checkpoint therapy for unresected esophageal cancers using nivolumab, a different PD-1 monoclonal antibody, has also been confirmed by high quality clinical trials.

This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy using pembrolizumab with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. And this study will provide valuable information for further clinical trials of preoperative pembrolizumab and other immune checkpoint therapy in esophageal cancer.
Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
Budesonide USP, the active ingredient of budesonide delayed-release capsules (enteric coated), is a synthetic corticosteroid. Budesonide is designated chemically as (RS)-11β, 16α, 17,21- tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided as a mixture of two epimers (22R and 22S). The molecular formula of budesonide is C25H34O6 and its molecular weight is 430.5. Its structural formula is:

Budesonide, USP is a white to off-white, odorless, crystalline powder that is practically insoluble in water and heptane, sparingly soluble in ethanol, and freely soluble in chloroform. Its partition coefficient between octanol and water at pH 5 is 1.6 x 103ionic strength 0.01.

Each capsule for oral administration contains 3 mg of micronized budesonide with the following inactive ingredients: acetyltributyl citrate, ethylcellulose aqueous dispersion, gelatin, iron oxide red, iron oxide yellow, methacrylic acid copolymer dispersion, polysorbate 80, simethicone emulsion, sodium lauryl sulfate, sugar spheres, talc, titanium dioxide and triethyl citrate. The capsule shell is printed with black pharmaceutical ink which contains following ingredients: iron oxide black, potassium hydroxide, propylene glycol and shellac.
This study aimed to compare primary care (PC) and infectious diseases (ID) provider adherence to HIV pre-exposure prophylaxis (PrEP) prescribing and monitoring parameters outlined in Centers for Disease Control/Department of Health and Human Services (CDC/DHHS) guidelines. This retrospective cohort analysis from 2017 to 2022 used prescription and laboratory order data to identify patients prescribed PrEP by PC or ID providers. Primary endpoints assessed were adherence to baseline and follow-up HIV monitoring recommendations in the 12 months following the initial PrEP prescription. Secondary endpoints included appropriate PrEP prescription order quantities (≤ 90-day supply), appropriate renal function monitoring, and identification of factors independently associated with follow-up HIV monitoring adherence. Of the 324 eligible patients identified, 112 received PrEP from an ID specialist and 212 from a PC provider. Patients prescribed PrEP from an ID specialist were more likely to have appropriately completed baseline HIV monitoring (OR = 2.56, 95% CI 1.20, 5.47), follow-up HIV monitoring (OR = 1.81, 95% CI 1.08, 3.05), and renal function monitoring (OR = 2.81, 95% CI 1.69, 4.68); The ID group was also more likely to have PrEP prescriptions appropriately authorized for a days' supply of ≤ 90 days (OR = 4.41, 95% CI 2.60, 7.48). Patients receiving PrEP care from ID specialists had better adherence to all assessed PrEP prescribing and monitoring recommendations compared to those receiving care from PC providers.
Patients with scheduled thoracic surgery are going to be enrolled for this study. Patients will be randomized and separated in two groups. Group I will receive thoracic paravertebral block, group II will receive rhomboid block. Each group will receive patient controlled analgesia with intravenous fentanyl. Patients will be monitored at postoperative 1st, 3rd, 6th, 12th, 24th hours and their VAS scores, adverse reactions like nausea and vomiting, total analgesic usage, additional analgesic need and time of the first report of pain will be filed. Then the two groups will be compared and evaluated.
Intervention participants will receive information focusing on asthma self-management, education, self-efficacy, and social support while in the hospital emergency room. Telephone reinforcement will occur for 8 weeks following study entry.
PURPOSE: A composition containing dried Rehmannia glutinosa extract is provided to remarkably reduce c-Fos expression and to prevent and treat drug addiction. CONSTITUTION: A pharmaceutical composition for preventing and treating drug addiction contains dried Rehmannia glutinosa extract as an active ingredient. The dried Rehmannia glutinosa extract is obtained using water, low alcohol of C1-C4, or mixture solvent thereof. The drug is cocaine, (meth)amphetamine, nicotine, morphine, alcohol, cannabis or caffeine. A health food for preventing and treating drug addiction contains the dried Rehmannia glutinosa extract as an active ingredient. The health food is manufactured in the form of powder, granule, tablet, capsule, syrup, or beverage.